Arcutis Biotherapeutics

ARQTApproved

Founded 2016arcutis.com

Arcutis Biotherapeutics, founded in 2016, is a public biotech company dedicated to meaningful innovation in medical dermatology. It leverages a proprietary topical formulation platform to develop targeted therapies, primarily PDE4 inhibitors, for chronic inflammatory skin conditions. The company has secured six FDA approvals for its ZORYVE franchise and is advancing a diverse pipeline, including a biologic candidate for atopic dermatitis, to address significant unmet patient needs.

Market Cap

$2.8B

Founded

2016

Focus

Small Molecules

ARQT · Stock Price

USD 22.21+5.02 (+29.20%)

Historical price data

AI Company Overview

Technology Platform

Proprietary dermatology drug development platform focused on biologically validated targets and optimized topical formulations (creams, foams) to deliver medication effectively into the skin.

Pipeline Snapshot

27 drugs in pipeline, 9 in Phase 3

Drug	Indication	Stage
Roflumilast Foam + Vehicle Foam	Seborrheic Dermatitis	Phase 3
Roflumilast Cream 0.05% + Vehicle Cream	Atopic Dermatitis Eczema	Phase 3
Roflumilast Foam 0.3% + Vehicle Foam	Scalp Psoriasis	Phase 3
Roflumilast Cream 0.15% + Vehicle Cream	Atopic Dermatitis Eczema	Phase 3
Roflumilast 0.3% cream + Vehicle Cream	Chronic Plaque Psoriasis	Phase 3

Funding History

Total raised: $411M

PIPE$200MUndisclosedFeb 15, 2021

IPO$126MUndisclosedJan 24, 2020

Series B$45MVivo CapitalFeb 15, 2018

Series A$40MFrazier Healthcare PartnersSep 15, 2016

FDA Approved Drugs

ZORYVENDADec 15, 2023

ZORYVENDAJul 29, 2022

Opportunities

Significant growth opportunities exist in expanding the ZORYVE franchise label into new populations (infants, pediatric psoriasis) and new disease areas (HS, vitiligo).

The successful development of ARQ-234 could open the large moderate-to-severe atopic dermatitis biologic market.

Geographic expansion outside the US presents another long-term opportunity.

Risk Factors

Key risks include commercial execution against entrenched competitors, clinical trial failures in pipeline programs, regulatory delays for supplemental applications, continued financial losses requiring additional capital, and intellectual property challenges.

Competitive Landscape

Arcutis competes with topical JAK inhibitors (e.g., Incyte's Opzelura), topical steroids, and calcineurin inhibitors. In biologics, it would face giants like Sanofi/Regeneron's Dupixent. Its differentiation lies in its topical PDE4 inhibitor's safety profile, once-daily convenience, and formulation expertise tailored for different skin sites and conditions.

Publications

Patents

Pipeline

FDA Approvals